JP5753159B2 - 内皮性機能／機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化 - Google Patents

内皮性機能／機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化 Download PDF

Info

Publication number
JP5753159B2
JP5753159B2 JP2012509026A JP2012509026A JP5753159B2 JP 5753159 B2 JP5753159 B2 JP 5753159B2 JP 2012509026 A JP2012509026 A JP 2012509026A JP 2012509026 A JP2012509026 A JP 2012509026A JP 5753159 B2 JP5753159 B2 JP 5753159B2
Authority
JP
Japan
Prior art keywords
drug treatment
death
fragment
pharmaceutical agent
mace
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012509026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526271A (ja
Inventor
ベルクマン アンドレアス
ベルクマン アンドレアス
シュトルック ヨアヒム
シュトルック ヨアヒム
ハルトマン オリファー
ハルトマン オリファー
ローク ン レオン
ローク ン レオン
Original Assignee
ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2012526271A publication Critical patent/JP2012526271A/ja
Application granted granted Critical
Publication of JP5753159B2 publication Critical patent/JP5753159B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5757—Vasoactive intestinal peptide [VIP] or related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012509026A 2009-05-05 2010-05-05 内皮性機能／機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化 Active JP5753159B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP09159472.1 2009-05-05
EP09159472 2009-05-05
EP09163269.5 2009-06-19
EP09163269 2009-06-19
EP09016143 2009-12-30
EP09016143.1 2009-12-30
PCT/EP2010/056081 WO2010128071A1 (en) 2009-05-05 2010-05-05 Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction

Publications (2)

Publication Number Publication Date
JP2012526271A JP2012526271A (ja) 2012-10-25
JP5753159B2 true JP5753159B2 (ja) 2015-07-22

Family

ID=42224880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012509026A Active JP5753159B2 (ja) 2009-05-05 2010-05-05 内皮性機能／機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化

Country Status (8)

Country Link
US (1) US9229013B2 (de)
EP (1) EP2427764B1 (de)
JP (1) JP5753159B2 (de)
CN (1) CN102428368B (de)
DK (1) DK2427764T3 (de)
ES (1) ES2643033T3 (de)
HK (1) HK1168146A1 (de)
WO (1) WO2010128071A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP3495822B1 (de) 2006-04-04 2023-12-20 Novilux, LLC Verfahren zur beurteilung des akuten myokardinfarkts basierend auf einer hochempfindlichen analyse des kardialen troponins
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
JP5678045B2 (ja) 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
CN103308673B (zh) * 2012-03-08 2017-05-31 思芬构技术有限公司 用于预测雌性对象中发生心血管事件的风险的方法
EP2657707A1 (de) * 2012-04-26 2013-10-30 B.R.A.H.M.S GmbH Biomarkers zur Diagnose, Vorhersage, Beurteilung und Therapiesynkopenschichtung
EP2904398B1 (de) * 2012-10-02 2018-04-11 SphingoTec GmbH Verfahren zur vorhersage des risikos von krebs bei einer weiblichen patientin
EP2943792B1 (de) * 2013-01-08 2018-11-14 SphingoTec GmbH Verfahren zur vorhersage des risikos von krebs oder zur diagnostizierung von krebs bei einem patienten
US9683018B2 (en) * 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
EP3024846A1 (de) * 2013-07-25 2016-06-01 Novartis AG Cyclische apelinderivate zur behandlung von herzinsuffizienz
TR201905773T4 (tr) * 2013-10-01 2019-05-21 Sphingotec Gmbh Bir majör advers kardiyak olayla karşılaşma riskinin tahmin edilmesi için bir usul.
US20170182129A1 (en) * 2014-04-03 2017-06-29 The Regents Of The University Of California Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure
CA2889826A1 (en) * 2014-06-20 2015-12-20 Emmanuel E. Egom Methods of treating pulmonary hypertention by administration of natriuretic peptide receptor c signaling pathway activators
WO2017089474A1 (en) * 2015-11-27 2017-06-01 Brahms Gmbh MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT
US11226343B2 (en) * 2016-04-08 2022-01-18 Biothelis Methods and kits for diagnosing postoperative pulmonary infections in patients who underwent surgery
SG11201900133WA (en) * 2016-07-08 2019-02-27 Sphingotec Gmbh Adrenomedullin for assessing congestion in a subject with acute heart failure
JP7271442B2 (ja) * 2017-05-30 2023-05-11 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 腎機能を診断またはモニターする方法、または腎機能障害を診断することを補助する方法
EP3438668A1 (de) 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnose und risikostratifizierung von pilzinfektionen
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
EP3682236A1 (de) * 2017-09-13 2020-07-22 B.R.A.H.M.S GmbH Proadrenomedullin als indikator für nierenersatztherapie bei kritisch kranken patienten
US20200271667A1 (en) * 2017-09-13 2020-08-27 B.R.A.H.M.S Gmbh Method for guidance of fluid therapy based on proadrenomedullin
US11327082B2 (en) 2017-09-13 2022-05-10 B.R.A.H.M.S Gmbh Proadrenomedullin as a marker for abnormal platelet levels
CN109283341A (zh) * 2018-10-17 2019-01-29 北京市心肺血管疾病研究所 一组预测心肌梗死患者的pci术后预后的生物标志物
CN109799338B (zh) * 2019-01-14 2022-02-11 湖南达道生物工程有限公司 一种适用于末梢血免疫层析定量检测的试纸及其应用
EP4023218A1 (de) * 2020-12-02 2022-07-06 S-Form Pharma Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
WO2024129564A1 (en) * 2022-12-13 2024-06-20 The Children's Medical Center Corporation Methods and compositions for the treatment of vascular anomalies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
DE102006034142A1 (de) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
PL2084543T3 (pl) * 2006-10-26 2018-04-30 B.R.A.H.M.S Gmbh Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DE102006060835A1 (de) * 2006-12-22 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung des akuten Koronarsyndroms mittels CT-proET-1 in Kombination mit NT-proBNP
DE102007010834A1 (de) * 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
EP2020603A1 (de) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Verfahren zur Einteilung von Risikoklassen bei stabiler Erkrankung der Koronaraterien

Also Published As

Publication number Publication date
ES2643033T3 (es) 2017-11-21
JP2012526271A (ja) 2012-10-25
CN102428368B (zh) 2015-04-22
DK2427764T3 (en) 2017-09-11
US20120142120A1 (en) 2012-06-07
EP2427764B1 (de) 2017-07-26
US9229013B2 (en) 2016-01-05
HK1168146A1 (en) 2012-12-21
CN102428368A (zh) 2012-04-25
EP2427764A1 (de) 2012-03-14
WO2010128071A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
JP5753159B2 (ja) 内皮性機能／機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化
JP5902479B2 (ja) マーカーペプチドのレベルを決定することによる脳卒中患者における予後判定及びリスク評価のための方法
JP6062532B2 (ja) 失神の診断、予後診断、評価、および治療の層別化のためのバイオマーカー
Gustafsson et al. Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography
EP2265957B1 (de) Pro-endothelin-1 für die vorhersage eines beeinträchtigten sauerstoffspitzenverbrauchs
KR20210044257A (ko) 심방 세동의 평가에서의 순환 bmp10 (골형성 단백질 10)
JP2013510289A (ja) 循環系事象と虚血性事象を鑑別するためのＮＴ−ｐｒｏＡＮＰおよびＳＦｌｔ−１
US20150247871A1 (en) Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
EP2737320B1 (de) FRAGMENTE AUS DER MITTE DES PRO-NATRIURETISCHEN PEPTIDS VOM A-TYP (MR-proANP) ZUR IDENTIFIZIERUNG VON PATIENTEN MIT VORHOFFLIMMERN VON EINER DAUER VON WENIGER ALS 48 STUNDEN
Nakamura et al. Independent prognostic value of pulmonary diffusing capacity in nonsmoking patients with chronic heart failure
US20090176249A1 (en) Method for detecting cardiac collateral formation
Yi et al. Correlates of N-terminal prohormone brain natriuretic peptides in African Americans with hypertensive chronic kidney disease: The African American Study of Kidney Disease and Hypertension
坂井健一郎 Brain natriuretic peptide as a predictor of cardioembolism in acute ischemic stroke patients: brain natriuretic peptide stroke prospective study

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131030

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150521

R150 Certificate of patent or registration of utility model

Ref document number: 5753159

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250